Systemic Versus Local Dexmedetomidine as An Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Block

Launched by ASWAN UNIVERSITY · Apr 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how well dexmedetomidine, a medication that helps with pain relief, works when given in two different ways during kidney surgeries. Researchers want to find out if giving it locally (right where the pain is) or systemically (through the bloodstream) alongside another pain medication called bupivacaine will provide better pain relief for patients undergoing kidney exploration surgeries.

To participate in this trial, individuals should be between 18 and 80 years old and be scheduled for kidney surgery. They should also be in good health, with a body mass index (BMI) under 35, and not have any serious health issues. However, those who are pregnant, have a history of drug or alcohol problems, or are receiving strong pain medications before the surgery won't be eligible. Participants in the study can expect to receive either local or systemic dexmedetomidine and will be monitored for their pain relief during and after the surgery. This trial is currently looking for volunteers to help researchers understand the best way to manage pain in these types of surgeries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • •. kidney exploration surgeries.
• • ASA I/II patients.
• • BMI \<35
• Exclusion Criteria:
• • Getting opioid analgesics prior to surgery.
• • Local infections at the site where needle for block is to be inserted.
• • ASAIII/IV.
• • Pregnancy.
• • History of drug addiction or alcohol abuse or a psychiatric illness,